122 related articles for article (PubMed ID: 17379968)
1. [Targeting therapy in rheumatoid arthritis].
Sugita T
Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):177-81. PubMed ID: 17379968
[No Abstract] [Full Text] [Related]
2. [Molecular targeting therapy in rheumatoid arthritis].
Mima T; Nakashima Y; Hanba Y; Ohya M; Negi S; Shigematsu T
Nihon Jinzo Gakkai Shi; 2012; 54(5):603-9. PubMed ID: 22991840
[No Abstract] [Full Text] [Related]
3. The updated guidelines on the use of rituximab in rheumatoid arthritis.
Lopez-Olivo MA; Tayar JH; Suarez-Almazor ME
Rheumatology (Oxford); 2011 Dec; 50(12):2153-4. PubMed ID: 21546350
[No Abstract] [Full Text] [Related]
4. [Management for TNF failure].
Mukai M
Nihon Rinsho; 2007 Jul; 65(7):1299-307. PubMed ID: 17642247
[TBL] [Abstract][Full Text] [Related]
5. [Proposal for biologic drugs therapy in rheumatoid arthritis].
Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S; Kaliterna DM; Hanih M; Novak S
Reumatizam; 2010; 57(1):29-35. PubMed ID: 20941938
[TBL] [Abstract][Full Text] [Related]
6. BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.
Bukhari M; Abernethy R; Deighton C; Ding T; Hyrich K; Lunt M; Luqmani R; Kiely P; Bosworth A; Ledingham J; Ostör A; Gadsby K; McKenna F; Finney D; Dixey J;
Rheumatology (Oxford); 2011 Dec; 50(12):2311-3. PubMed ID: 21546351
[No Abstract] [Full Text] [Related]
7. Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice: an open label observational study.
Assous N; Gossec L; Dougados M; Kahan A; Allanore Y
Clin Exp Rheumatol; 2007; 25(3):504. PubMed ID: 17631755
[No Abstract] [Full Text] [Related]
8. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Belmonte Serrano MA; Pincus T
Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342
[No Abstract] [Full Text] [Related]
9. Cryptococcal meningitis in an HIV-negative patient with rheumatoid arthritis treated with rituximab.
Wingfield T; Jani M; Krutikov M; Mayer J; Uriel A; Marks J; Ustianowski AP
Rheumatology (Oxford); 2011 Sep; 50(9):1725-7. PubMed ID: 21700684
[No Abstract] [Full Text] [Related]
10. Efficacy of rituximab on pulmonary nodulosis occurring or increasing in patients with rheumatoid arthritis during anti-TNF-α therapy.
De Stefano R; Frati E; Nargi F; Menza L
Clin Exp Rheumatol; 2011; 29(4):752-3. PubMed ID: 21906436
[No Abstract] [Full Text] [Related]
11. A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C.
Chen YM; Chen HH; Chen YH; Hsieh TY; Hsieh CW; Hung WT; Lan JL; Chen DY
Ann Rheum Dis; 2015 Mar; 74(3):626-7. PubMed ID: 25452310
[No Abstract] [Full Text] [Related]
12. [Recent topics on new biological agents for treatment of rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2418-23. PubMed ID: 19149039
[No Abstract] [Full Text] [Related]
13. [Recent progress in clinical trials for rheumatic diseases].
Tanaka Y
Nihon Rinsho; 2009 Mar; 67(3):619-25. PubMed ID: 19280942
[TBL] [Abstract][Full Text] [Related]
14. [Rituximab in patients with rheumatoid arthritis: systematic review].
Brodszky V; Czirják L; Géher P; Hodinka L; Kárpáti K; Péntek M; Poór G; Szekanecz Z; Gulácsi L
Orv Hetil; 2007 Oct; 148(40):1883-93. PubMed ID: 17905683
[TBL] [Abstract][Full Text] [Related]
15. Patients' groups welcome NICE decisions on arthritis and multiple sclerosis drugs.
Cole A
BMJ; 2007 Sep; 335(7617):416-7. PubMed ID: 17762016
[No Abstract] [Full Text] [Related]
16. Targeted therapy in rheumatoid arthritis.
Köller MD
Wien Med Wochenschr; 2006 Jan; 156(1-2):53-60. PubMed ID: 16465614
[TBL] [Abstract][Full Text] [Related]
17. [TNF targetting therapy for rheumatoid arthritis].
Takeuchi T
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1787-94. PubMed ID: 17037316
[No Abstract] [Full Text] [Related]
18. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of new biologics on bone destruction in rheumatoid arthritis].
Kazuyoshi S; Tanaka Y
Clin Calcium; 2009 Mar; 19(3):372-80. PubMed ID: 19252247
[TBL] [Abstract][Full Text] [Related]
20. [Clinical development and future perspective of biological agents].
Takeuchi T
Nihon Rinsho; 2007 Jul; 65(7):1185-8. PubMed ID: 17642230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
